Review Series 10.1172/JCI97953

Role of prostanoids in gastrointestinal cancer

Dingzhi Wang1 and Raymond N. DuBois1,2

1Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina, USA.

2Department of Research and Division of Gastroenterology, Mayo Clinic, Scottsdale, Arizona, USA.

Address correspondence to: Raymond N. DuBois, 601 Clinical Science Building, 96 Jonathan Lucas Street, Suite 601, Charleston, South Carolina 29425, USA. Phone: 843.792.2842; Email: duboisrn@musc.edu.

Find articles by Wang, D. in: JCI | PubMed | Google Scholar

1Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina, USA.

2Department of Research and Division of Gastroenterology, Mayo Clinic, Scottsdale, Arizona, USA.

Address correspondence to: Raymond N. DuBois, 601 Clinical Science Building, 96 Jonathan Lucas Street, Suite 601, Charleston, South Carolina 29425, USA. Phone: 843.792.2842; Email: duboisrn@musc.edu.

Find articles by DuBois, R. in: JCI | PubMed | Google Scholar

First published May 7, 2018 - More info

Published in Volume 128, Issue 7 (July 2, 2018)
J Clin Invest. 2018;128(7):2732–2742. https://doi.org/10.1172/JCI97953.
Copyright © 2018, American Society for Clinical Investigation

First published May 7, 2018

Chronic inflammation is a risk factor for gastrointestinal cancer and other diseases. Most studies have focused on cytokines and chemokines as mediators connecting chronic inflammation to cancer, whereas the involvement of lipid mediators, including prostanoids, has not been extensively investigated. Prostanoids are among the earliest signaling molecules released in response to inflammation. Multiple lines of evidence suggest that prostanoids are involved in gastrointestinal cancer. In this Review, we discuss how prostanoids impact gastrointestinal cancer development. In particular, we highlight recent advances in our understanding of how prostaglandin E2 induces the immunosuppressive microenvironment in gastrointestinal cancers.

Preview pages

Reset
Page preview
2733 Page 2732 Back

Continue reading with a subscription.

A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.

Already subscribed?

Click here to sign into your account.

Don't have a subscription?

Please select one of the subscription options, which includes a low-cost option just for this article.

At an institution or library?

If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).

Problems?

Please try these troubleshooting tips.

  • Purchase this article
  • $10
  • Purchasing this article will give you full access for the calendar year.
  • Purchase article
  • Purchase Site Pass
  • $25
  • This will give you access to every article on the site for 24 hours.
  • Order site pass
  • Online subscription
  • $95
  • Individual online subscriptions give you full online access for the calendar year.
  • Order Online
  • Print subscription
  • $795
  • Individual print subscriptions give you the print journal and full online access for the year.
  • Print + Online
  • JCI This Month subscription
  • $125
  • JCI This Month is a 16- to 20-page overview of the articles published each month
  • Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
  • *Price outside U.S. and Canada: $225.
  • JCI This Month + Online
Advertisement